L3VLUP
ProSign in

IRMD · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

IRMDLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • IRMD
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterIRMDLLY
Q3 2020none listed holders, n.a.33 holders, $14.1bn
Q4 2020none listed holders, n.a.29 holders, $17.3bn
Q1 2021none listed holders, n.a.24 holders, $23.0bn
Q2 2021none listed holders, n.a.24 holders, $27.8bn
Q3 20211 holders, $1.1m31 holders, $29.9bn
Q4 20211 holders, $32m31 holders, $34.7bn
Q1 20221 holders, $6.4m24 holders, $35.3bn
Q2 20221 holders, $5.6m33 holders, $42.7bn
Q3 20221 holders, $5.0m31 holders, $43.4bn
Q4 20221 holders, $4.7m31 holders, $46.6bn
Q1 20231 holders, $7.1m33 holders, $44.3bn
Q2 20231 holders, $8.7m37 holders, $59.6bn
Q3 20233 holders, $34m44 holders, $67.6bn
Q4 20233 holders, $36m45 holders, $73.6bn
Q1 20241 holders, $6.9m41 holders, $95.3bn
Q2 20241 holders, $6.3m43 holders, $110bn
Q3 20241 holders, $6.9m45 holders, $107bn
Q4 20241 holders, $7.8m46 holders, $93.9bn
Q1 20251 holders, $8.2m42 holders, $98.4bn
Q2 20252 holders, $11m43 holders, $93.2bn
Q3 20253 holders, $47m39 holders, $86.7bn
Q4 20253 holders, $62m41 holders, $123bn
Q1 20264 holders, $60m39 holders, $106bn
Q2 20262 holders, $38m44 holders, $132bn
IRMD

Iradimed Corp

Holders
3
Reported value
$62m
Buyers
13
Sellers
8

Breadth +5 among 92 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
LLY

Eli Lilly & Co

Holders
41
Reported value
$123bn
Buyers
25
Sellers
22

Breadth +3 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2025

Among the 41 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only IRMD (0)

None.

Only LLY (38)

AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Artisan Partners LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Fidelity (FMR LLC), Freestone Grove Partners LP, GAMCO Investors Inc, Harris Associates LP, Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, Millennium Management LLC, Moore Capital Management LP, and 13 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →